Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions

Alabiad, Mohamed Ali; Harb, Ola A.; Taha, Heba; Shafaay, Basant Sh El; Gertallah, Loay M.; Salama, Nashaat M.

doi:10.1007/s12253-018-0534-1

Cited by 14 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in line with a growing body of evidence regarding the negative prognostic significance of SCF in solid tumors e.g., hepatocellular carcinoma, colorectal carcinoma, prostate cancer and pancreatic ductal adenocarcinoma. [42][43][44][45] Moreover, a significant association was identified between SCF overexpression and trisomy 12, which might be attributed to a gene dosage effect considering that the KITLG gene locus is located on chromosome 12. 12 Stimulation of immune receptors (BcR, TLR9, CD40) was found to modulate the levels of both membrane and soluble SCF, thus highlighting the dynamic nature of SCF expression in CLL.…”

Section: Discussionmentioning

confidence: 98%

Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia

et al. 2020

View full text Add to dashboard Cite

The inflammatory cytokine Stem Cell Factor (SCF, ligand of c-kit receptor) has been implicated as a pro-oncogenic driver and an adverse prognosticator in several human cancers. Increased SCF levels have recently been reported in a small series of patients with chronic lymphocytic leukemia (CLL), however its precise role in CLL pathophysiology remains elusive. In this study, CLL cells were found to predominantly express the membrane isoform of SCF that is known to elicit a more robust activation of the c-kit receptor. SCF was significantly overexpressed in CLL cells compared to healthy tonsillar B cells whilst it correlated with adverse-prognostic biomarkers, shorter time-to-first treatment and shorter overall survival. Activation of immune receptors and long-term cell-cell interactions with the mesenchymal stroma led to an elevation of SCF primarily in adverse-prognostic CLL cases. On the contrary, suppression of oxidative stress and the BTK inhibitor Ibrutinib negated SCF levels. Interestingly, SCF significantly correlated with mitochondrial dynamics and HIF-1α which have previously been linked with clinical aggressiveness in CLL. SCF was able to elicit direct biological effects in CLL cells affecting redox homeostasis and cell proliferation. Overall, the aberrantly expressed SCF in CLL cells emerges as a key response regulator to microenvironmental stimuli whilst correlating with poor prognosis. On these grounds, specific targeting of this inflammatory molecule could serve as a novel therapeutic approach in CLL.

show abstract

Section: Discussionmentioning

confidence: 98%

Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, prostaglandin 15d-PGJ 2 acts as a tumor suppressor by inhibiting AR [93,94]. Finally, a cohort study with 50 patients showed that higher COX-2 levels were significantly associated with higher PSA (prostate-specific antigen), higher Gleason grade, worse prognosis, higher probability of relapse after treatment, and shorter survival time [95].…”

Section: Prostaglandins In Endocrine Tissue Cancermentioning

confidence: 99%

The Role of Prostaglandins in Different Types of Cancer

Jara-Gutiérrez

Baladrón

2021

Cells

View full text Add to dashboard Cite

The prostaglandins constitute a family of lipids of 20 carbon atoms that derive from polyunsaturated fatty acids such as arachidonic acid. Traditionally, prostaglandins have been linked to inflammation, female reproductive cycle, vasodilation, or bronchodilator/bronchoconstriction. Recent studies have highlighted the involvement of these lipids in cancer. In this review, existing information on the prostaglandins associated with different types of cancer and the advances related to the potential use of them in neoplasm therapies have been analyzed. We can conclude that the effect of prostaglandins depends on multiple factors, such as the target tissue, their plasma concentration, and the prostaglandin subtype, among others. Prostaglandin D2 (PGD2) seems to hinder tumor progression, while prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2α) seem to provide greater tumor progression and aggressiveness. However, more studies are needed to determine the role of prostaglandin I2 (PGI2) and prostaglandin J2 (PGJ2) in cancer due to the conflicting data obtained. On the other hand, the use of different NSAIDs (non-steroidal anti-inflammatory drugs), especially those selective of COX-2 (cyclooxygenase 2), could have a crucial role in the fight against different neoplasms, either as prophylaxis or as an adjuvant treatment. In addition, multiple targets, related to the action of prostaglandins on the intracellular signaling pathways that are involved in cancer, have been discovered. Thus, in depth research about the prostaglandins involved in different cancer and the different targets modulated by them, as well as their role in the tumor microenvironment and the immune response, is necessary to obtain better therapeutic tools to fight cancer.

show abstract

“…In support of our results, Sun et al (28) and Li et al (29) found a significant association between the expression of CD133 and LN. The cancer stem cell tumorogenicity concept could elucidate the reasons why traditional chemotherapies fail to eradicate cancer (30) . In the course of this research, we found that high expression of CD133 was highly correlated with chemotherapeutic resistance, which made a high expression of CD133 to be a strong prognostic and predictive marker for conventional chemotherapeutic failure in stage III colorectal carcinoma patients.…”

Section: Figure (2): Immunohistochemistry Of Cd133 Expression In Colo...mentioning

confidence: 99%

The Prognostic Value of Cancer Stem Cell Marker, Cluster of Differentiation 133 Expression in Stage III Colorectal Carcinoma

Alabiad

Said²,

Elhasadi³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is the 3 rd most prevalent diagnosed cancer and the 4 th leading cause of cancer-related deaths globally. Nodal staging is significantly more essential in rectal cancer that detects most the therapy options.Objectives: This study aimed to evaluate CD133 expression in the colorectal carcinoma stage III using immunohistochemistry as well as its relationship to clinicopathological characteristics and patient outcomes. Patients and Methods:The study includes 60 cases with stage III CRC five years after surgical removal of the tumor and regular follow-up with the Departments of Medical and Clinical Oncology where clinicopathological and prognostic data are collected from the archives. The patients were classified into two groups, GI includes 22 CRC patients with relapse, and GII includes 38 CRC patients without relapse. Sixty archive paraffin blocks of primary resection and metastatic lymph nodes were extracted from the archives of the Pathology Department processed for CD133 immunohistochemistry. CD133 expression levels were assessed, analyzed, and correlated with clinicopathological and prognostic criteria. Results: Positive CD133 expression was significantly linked with old age ( P=0.034 ), large tumor size ( p < 0.001), perineural invasion (p = 0.0017), lympho-vascular invasion ( P < 0.001 ), high-grade ( p < 0.001 ), resistance to chemotherapy (p = 0.011), lymph nodes metastasis and relapse (p = 0.005*) and DFS (p = 0.005) Conclusion: CD133 expression in colorectal carcinoma is related to tumour progression and is considered a marker of poor prognosis and a strong indicator of relapse and poor survival. Moreover, CD133 stem cell marker may act as a targeted therapy in chemotherapeutic resistance patients with colorectal carcinoma.

show abstract

Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions

Cited by 14 publications

References 29 publications

Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia

Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia

The Role of Prostaglandins in Different Types of Cancer

The Prognostic Value of Cancer Stem Cell Marker, Cluster of Differentiation 133 Expression in Stage III Colorectal Carcinoma

Contact Info

Product

Resources

About